跳至主要内容
临床试验/NCT00085488
NCT00085488已完成1 期

En Vivo Matured Dendritic Cell Therapy in Patients With Melanoma

Dartmouth-Hitchcock Medical Center2 个研究点 分布在 1 个国家开始时间: 2004年2月最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
试验地点
2
主要终点
Ex Vivo Matured Dendritic Cell Therapy in Patients with Melanoma

研究概览

简要总结

RATIONALE: Vaccines made from a patient's dendritic cells and tumor cells may make the body build an immune response to kill tumor cells.

PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with stage III or stage IV melanoma.

详细描述

OBJECTIVES:

Primary

  • Determine the dose-limiting toxicity and the maximum tolerated dose of autologous dendritic cells pulsed with autologous tumor cell lysate in patients with stage III or IV melanoma.
  • Determine the safety and tolerability of this therapy in these patients.

Secondary

  • Determine the immune response, in terms of the type and degree of T-cell proliferation and delayed-type hypersensitivity responses, in patients treated with this therapy.

研究设计

研究类型
Interventional
主要目的
Treatment

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Ex Vivo Matured Dendritic Cell Therapy in Patients with Melanoma

时间窗: 2005-2006

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验